Answered You can hire a professional tutor to get the answer.
Hello, I am looking for someone to write an essay on Monoclonal antibodies to epidermal growth factor receptor (EGFR) such as Cetuximab, are used to treat solid tumours but resistance to this treatmen
Hello, I am looking for someone to write an essay on Monoclonal antibodies to epidermal growth factor receptor (EGFR) such as Cetuximab, are used to treat solid tumours but resistance to this treatment is a major clinical problem. It is essential to understand the mechanisms supporting the various forms of. It needs to be at least 2000 words.
ly against Epidermal Growth Factor Receptor (EGFR) in order to treat cancers such as metastatic colorectal cancer or lung cancer (Jean and Shah, 2008). In the cancer signalling pathway, EGFR, which belongs to the ErbB family of proteins, is activated upon binding with other receptors such as the peptide growth receptors (Normanno et al, 2006). Studies have shown that in patients with cancer the EGFR associated with peptide growth receptors is over expressed. Therefore, monoclonal antibodies which had been developed as inhibitors of EGFR along with conventional chemotherapy helped in prolongation of life in patients afflicted with cancer. However, complexity arose when certain patients with genetic alterations such as mutation in K-ras or PTEN instability showed resistance to the administration of the monoclonal antibodies which inhibited the success of the anti-cancer therapies and added to patient mortality. Several researchers focussed their studies on strategies to eliminate the resistance developed by the patients which called for an in-depth understanding of the resistance pathways. This paper, focuses particularly on two such studies- Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells by Kim et al (2010) and MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential Therapies for .KRAS .Mutated Colorectal Cancer That Is Resistant to EGFR Monoclonal Antibody Therapy by Yoon et al (2011).
Both of the papers have devised novel way to understand the development of resistance against treatment. In terms of theory both the papers looked into different aspects of the problem in terms of activation of EGFR. Yoon et al focused to understand the KRAS mutation induced resistance in colorectal cancer and come up with a plausible method to solve the problem. Colorectal cancer is a common form of cancer and has shown elevated expression of EGRF in the cells. However, the molecular therapy
